Venus Medtech Narrows Losses but Revenue and Margins Slide in 2025

Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has shared an announcement.

Venus Medtech reported a sharp year-on-year decline in revenue to RMB306.8 million for 2025, down 34.8%, with gross profit falling 42.4% as commercialization profit margins were squeezed to just 0.5% on a non-IFRS basis. The company nonetheless narrowed its net loss to RMB407.7 million from RMB717.4 million, aided by lower operating expenses, improved non-IFRS EBITDA and reduced other expenses, signaling some progress in cost control despite weaker top-line performance.

Research and development spending, while reduced from the prior year, remained substantial, underscoring the company’s continued investment in its product pipeline amid a challenging revenue environment. For stakeholders, the results highlight ongoing pressure on commercialization efficiency and profitability, but also a slower cash burn trajectory and operational adjustments that could be significant for Venus Medtech’s medium-term financial sustainability and competitive positioning in the cardiovascular device market.

The most recent analyst rating on (HK:2500) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.

More about Venus Medtech (Hangzhou), Inc. Class H

Venus Medtech (Hangzhou) Inc. is a China-based medical device company listed in Hong Kong and focused on the development and commercialization of innovative cardiovascular implants. The group generates revenue primarily from sales of its heart valve and related interventional products, targeting both domestic and international markets in the structural heart disease segment.

Average Trading Volume: 1,763,413

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$811.5M

For a thorough assessment of 2500 stock, go to TipRanks’ Stock Analysis page.